期刊
CANCER JOURNAL
卷 10, 期 1, 页码 20-26出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00130404-200401000-00006
关键词
-
类别
资金
- NCI NIH HHS [CA45745] Funding Source: Medline
BACKGROUND Neurofibromatosis type 2 is a group of tumors caused by loss-of-function mutations of a tumor suppressor gene encoding NF2/ merlin. Development of chemotherapeutics for this disease, which often threatens the life of young children, has been hampered by a limited information on the signaling function of NF2. NF2 can inhibit Ras-induced malignant transformation. However, the primary (signaling) target of NF2 in the oncogenic pathway has not been previously identified. RESULTS Here, using a series of NF2 constructs, we show that NF2 inhibits directly the Rac/CDC42-depenclent Ser/Thr kinase PAK1, which is essential for both Ras transformation and neurofibromatosis type 1 (NF1), through two separate domains. A mutant of NF2, that lacks the PAK1-inhibiting domain of 78 amino acids (NF78C, residues 447-524), fails to suppress Ras transformation. Furthermore, PAK1-specific inhibitors CEP-1347 and WR-PAK18 selectively inhibit the growth of NF2-deficient cancer cells, but not NF2-positive cells. CONCLUSIONS These results suggest that PAK1 is essential for the malignant growth of NF2-deficient cells, and that PAK1-blocking drugs could be potentially useful for the treatment of neurofibromatosis types 2, in addition to Ras-induced cancers and neurofibromatosis type 1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据